BCIQ Profiles

Company Profile Report
0423 ODAC meeting
BioCentury & Getty Images


ODAC meeting on checkpoint inhibitors could affect future of accelerated approval

Six indications for three drugs will be reviewed

Six indications for three drugs will be reviewed.

Apr 24, 2021 | 2:28 AM GMT

The integrity and future of FDA’s accelerated approval pathway will be on trial at next week’s Oncologic Drugs Advisory Committee meeting.

ODAC will be making recommendations about retaining or withdrawing six accelerated approvals for three PD-1

Read the full 736 word article

How to gain access

Continue reading with a
two-week free trial.